Technical Analysis for DAWN - Day One Biopharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 13.59 | -0.22% | -0.03 |
DAWN closed up 0.74 percent on Wednesday, November 20, 2024, on 51 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | -0.22% | |
| Lower Bollinger Band Walk | Weakness | -0.22% | |
| Oversold Stochastic | Weakness | -0.22% | |
| Lower Bollinger Band Walk | Weakness | 0.52% | |
| Inside Day | Range Contraction | 0.52% | |
| Lower Bollinger Band Touch | Weakness | 0.52% | |
| Oversold Stochastic | Weakness | 0.52% | |
| MACD Bearish Centerline Cross | Bearish | 4.46% | |
| Lower Bollinger Band Walk | Weakness | 4.46% | |
| Below Lower BB | Weakness | 4.46% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 2 hours ago |
| Fell Below Previous Day's Low | about 3 hours ago |
| Down 2 % | about 3 hours ago |
| Down 1% | about 4 hours ago |
| Possible NR7 | about 24 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 10/30/2024
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Enzymes Signal Transduction Protein Kinase Inhibitor Protein Kinase Kinase
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Enzymes Signal Transduction Protein Kinase Inhibitor Protein Kinase Kinase
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 18.0699 |
| 52 Week Low | 11.3 |
| Average Volume | 1,126,645 |
| 200-Day Moving Average | 14.62 |
| 50-Day Moving Average | 14.37 |
| 20-Day Moving Average | 14.67 |
| 10-Day Moving Average | 14.63 |
| Average True Range | 0.76 |
| RSI (14) | 40.83 |
| ADX | 27.93 |
| +DI | 19.89 |
| -DI | 25.52 |
| Chandelier Exit (Long, 3 ATRs) | 14.49 |
| Chandelier Exit (Short, 3 ATRs) | 15.14 |
| Upper Bollinger Bands | 16.39 |
| Lower Bollinger Band | 12.95 |
| Percent B (%b) | 0.19 |
| BandWidth | 23.41 |
| MACD Line | -0.20 |
| MACD Signal Line | 0.05 |
| MACD Histogram | -0.2525 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 14.21 | ||||
| Resistance 3 (R3) | 14.17 | 13.94 | 14.11 | ||
| Resistance 2 (R2) | 13.94 | 13.79 | 13.96 | 14.07 | |
| Resistance 1 (R1) | 13.78 | 13.70 | 13.86 | 13.82 | 14.04 |
| Pivot Point | 13.55 | 13.55 | 13.59 | 13.57 | 13.55 |
| Support 1 (S1) | 13.39 | 13.40 | 13.47 | 13.43 | 13.20 |
| Support 2 (S2) | 13.16 | 13.31 | 13.18 | 13.17 | |
| Support 3 (S3) | 13.00 | 13.16 | 13.13 | ||
| Support 4 (S4) | 13.04 |
